Segment Reporting
April 20, 2026
Why serious investors should read segment notes to discover where the real business quality sits, and how Titan’s geographic split strengthens trust in the disclosure.
April 19, 2026
Titan Biotech disclosed only one primary operating segment in FY25, a quiet but powerful sign that the business remains easier to understand and monitor than many small-cap peers.
